At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 63 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
Researchers at University College London are studying new markers in the body, called biomarkers, in people having Targeted Lung Health Checks. The study is about lung cancer. It will assess these new biomarkers in people taking part in the checks.
Who can take part
- You have been to one or more appointments as part of the NCL NHS Targeted Lung Health Check (TLHC) programme
- You are aged between 55 and 74 years (right up to the day before your 75th birthday)
- You are able to understand the study and give written permission (consent) to take part
Who may not be able to
- You choose not to take part in ALPINE
- You are not able to understand the study or give written permission (consent)
- Your doctor thinks you are not well enough or not suitable to join ALPINE
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 55 Years to 74 Years
- Who
- All
- Number of participants
- 10,000
- Started
- 2023-08-01
- Last checked
- 2024-10
Plain English Summary
What is this study?
- • Testing a new treatment for lung cancer
- • Clinical study - 10,000 participants
- • Low-dose CT (LDCT) screening for lung cancer (LCS) has been shown to reduce lung cancer specific mortality in multiple randomised controlled trials
Who can take part?
- • Ages 55 Years to 74 Years
- • Diagnosed with lung cancer
Where?
- • London - University College London Hospitals NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Low-dose CT (LDCT) screening for lung cancer (LCS) has been shown to reduce lung cancer specific mortality in multiple randomised controlled trials. However, although LDCT screening has been demonstrated to reduce cancer- specific mortality, there remain outstanding questions regarding how screening can be implemented. In particular, indeterminate nodules are common, and can be challenging to distinguish from benign nodules on CT appearances alone. Furthermore, distinguishing cancers which are likely to become clinically significant from those that will remain indolent is challenging, but essential to prevent over-treatment and overdiagnosis. There is significant interest in using a multi-modal approach to LCS, incorporating biomarkers obtained from minimally-invasive samples alongside LDCT to improve ability to recognise clinically-significant lung cancers at an early stage. The Targeted Lung Health Check (TLHC) programme is an NHS programme with the aim of using LDCT screening in appropriately high-risk individuals to improve early diagnosis and survival in lung cancer. The North Central London TLHC programme started in December 2022. The purpose of the ALPINE study is to develop a platform to allow collection of minimally-invasive samples from participants undergoing screening within the North Central London TLHC programme. The use of such biomarkers in the diagnosis of lung cancer is a rapidly developing field and novel techniques and technologies are continuously under development. The ALPINE study will generate a cohort with matched biosamples, CT scans and clinical data which will be uniquely well placed to serve to develop or validate biomarkers in lung cancer screening and risk prediction.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 55 Years - 74 Years
- Who can join: All genders
What the study is looking for
- ✓Attended one of more visits as part of the NCL NHS TLHC programme
- ✓Adults aged between 55 years and 74 years and 364 days
- ✓Have capacity and can provide written consent
Who cannot take part
- ✗Declines participation in ALPINE
- ✗Lacking capacity and unable to provide written consent
- ✗Patients who are considered by the clinician to be unfit/not suitable for enrolment in ALPINE
See the full criteria
Where Is This Study? (1 UK site)
University College London Hospitals NHS Foundation Trust
London, United Kingdom